How to divide and conquer -F-star’s asset centric business model and their recent big deal with BMS.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How to divide and conquer -F-star’s asset centric business model and their recent big deal with BMS.
Released on: January 30, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    F-star develops novel bispecific antibodies to improve the treatment of serious diseases, with a focus on immuno-oncology and inflammation.
  • Summary
  • Transcript
  • Participants
  • Company
F-star develops novel bispecific antibodies to improve the treatment of serious diseases, with a focus on immuno-oncology and inflammation. John Haurum explains to PharmaVentures' Adrian Dawkes how their Modular Antibody Technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The power of the technology, combined with biology expertise, allows F-star to identify the most appropriate target combinations that will have the potential for the greatest therapeutic benefit to patients. They also discuss the F-star asset centric business model and their recent deal with BMS.
F-star develops novel bispecific antibodies to improve the treatment of serious diseases, with a focus on immuno-oncology and inflammation. John Haurum explains to PharmaVentures' Adrian Dawkes how their Modular Antibody Technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The power of the technology, combined with biology expertise, allows F-star to identify the most appropriate target combinations that will have the potential for the greatest therapeutic benefit to patients. They also discuss the F-star asset centric business model and their recent deal with BMS.
John Haurum
F-star
MD from University of Aarhus, Denmark D.Phil. in immunology from the Institute of Molecular Medicine, University of Oxford, England Experience in building and leading antibody biotech companies, including discovery, development, financing and business development Successfully managed several monoclonal and oligoclonal antibody products into clinical development and collaborations with both Genentech and Meiji Previous experience includes: VP Research, Biologics Products at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company Co-founder and Chief Scientific Officer of Symphogen A/S
F-star